LKFT logo

LAKEFRONT BIOTHERAPEUTIC-ADR

LKFTNASDAQ
🏆 #2011 by market capUS Equity
$73.84▲ $3.74 (+5.07%)
Simulated price
🔔
Track LKFT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.1%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.96B
Small Cap
📈Revenue Growth (YoY)
+303.5%
High Growth
📊Gross Margin
94.9%
High
💵FCF Margin
-19.9%
Thin
⚖️P/S Ratio
1.7x
Cheap
Otter Score
44
Weak
No chart data available for LKFT.

Trading Snapshot

Day Range
$72.97 – $74.75
52-Week Range
$25.68 – $37.78
Volume
$2.32B
Avg Volume
$2.66B
Shares Outstanding
65.9M
Next Earnings
Dec 16, 2026

Fundamentals Snapshot

Annual Revenue
$1.11B
Last Q Revenue
$12M
P/E Ratio
2.9
P/S Ratio
1.7x
EPS (TTM)
$8.09
Dividend Yield
0.00%
Dilution (1yr)
+220749.3%

Why Investors Own LKFT

  • ✓High-growth profile — revenue up +0.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 36% gross margin and 30% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LKFT logo

LAKEFRONT BIOTHERAPEUTIC-ADR

LKFT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1B▲ +303.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.3%▲ +11.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$501M▼ −366.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
65.9M▲ +220749.3% YoY
StockOtter · stockotter.space

About LAKEFRONT BIOTHERAPEUTIC-ADR

Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$72.40
▼ −1.9% Downside
High Target$80.04
Low Target$57.95
Based on 9 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

LAKEFRONT BIOTHERAPEUTIC-ADR tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift LKFT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

LAKEFRONT BIOTHERAPEUTIC-ADR announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.